Andere talen Qurient Co., Ltd.

Aandelen

A115180

KR7115180002

slotkoers Korea S.E. Andere beurzen 00:00:00 14-06-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
3.680 ^KRW	-2,00%		-8,57%	-21,20%

21/05	Qurient Therapeutics gaat een CRADA aan met het National Cancer Institute om samen te werken aan een fase 1/2 klinische studie van Q901 in combinatie met TROP2-ADC	CI
2023	Qurient Co., Ltd. Rapporteert winstresultaten voor het eerste kwartaal eindigend op 31 maart 2023	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Qurient Therapeutics Enters CRADA with the National Cancer Institute to Collaborate on a Phase 1/2 Clinical Study of Q901 in Combination with TROP2-ADC	21/05
Qurient Co., Ltd. announced that it has received KRW 13.499996307 billion in funding from DongKoo Bio & Pharma Co., Ltd.	17/05
Qurient Co., Ltd. announced that it expects to receive KRW 13.499998256 billion in funding from DongKoo Bio & Pharma Co., Ltd. and another investor	12/04
Qurient Co., Ltd. announced that it has received KRW 5.999997188 billion in funding from Premier Partners, LLC	27/12
Qurient Co., Ltd. announced that it expects to receive KRW 5.99999268 billion in funding from Premier Partners, LLC	19/12
Qurient Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	12-05-23
Qurient Co. Ltd. and TB Alliance Announces Exclusive License Agreement for Telacebec	03-02-23
Qurient Co., Ltd. Announces Dosing of First Patient in Q702 in Combination with KEYTRUDA® in a Phase 1b/2 Clinical Study for the Treatment of Patients with Solid Tumors	31-01-23
Qurient Co. Ltd Announces Dosing of First Patient in Q901 Phase 1/2 Clinical Study for the Treatment of Patients with Solid Tumors	01-12-22
Qurient Announces Dosing of First Patient in Q901 Phase 1/2 Clinical Study for the Treatment of Patients with Solid Tumors	01-12-22
Qurient Co., Ltd. Enters into A Clinical Collaboration Agreement with Merck & Co., Inc. for Clinical Study of Q901	14-09-22
Qurient Co. Ltd. U.S. FDA Clearance of IND Application for Q901, a Novel Cancer Therapy	08-02-22
Qurient Co., Ltd. announced that it has received KRW 12.5 billion in funding from CureBio Co.,Ltd., and other investors	17-12-21
Qurient Co., Ltd. announced that it expects to receive KRW 12.5 billion in funding from CureBio Co.,Ltd., and other investors	09-12-21
Qurient Co. Ltd. Enters into A Clinical Collaboration Agreement with MSD	23-11-21
Qurient Co., Ltd.(KOSDAQ:A115180) dropped from S&P Global BMI Index	07-07-21
Qurient Co., Ltd. Enrolls First Patient in Q702 U.S. Phase 1 Study	26-01-21
Qurient Co., Ltd. announced that it expects to receive KRW 59.99986805 billion in funding from a group of investors	22-09-20
QLi5 Therapeutics GmbH announced that it expects to receive KRW 2.039115 billion in funding from Qurient Co., Ltd.	11-06-20
Qurient Co., Ltd. Announces U.S. FDA Clearance of IND Application for Q702	26-05-20

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Qurient Co., Ltd.

Aandelen

A115180

KR7115180002

Andere talen

Filters